Compare ASE Technology Holding Co Ltd (ASX) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Incyte Corporation — how do they compare? ASE Technology Holding Co Ltd trades at $41.78 (market cap $92.88B), while Incyte Corporation trades at $116.99 (market cap $23.32B). The key difference: ASE Technology Holding Co Ltd is far larger — about 4× Incyte Corporation's market cap, and ASE Technology Holding Co Ltd pays a 0.98% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ASX | INCY | |
|---|---|---|
Market Cap | $92.88B | $23.32B |
Sector | Technology | Health |
52-Week High | $45.12 | $118.52 |
52-Week Low | $9.50 | $67.38 |
Enterprise Value | $97.32B | $19.34B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.
Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.
INCY trades at $116.71, down 1.53% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust revenue of $5.14 billion in 2025, with a net income margin of 26.71%, and recent news highlights regulatory approvals and portfolio expansion, including the acquisition of Vega Therapeutics.
The outlook is positive, driven by earnings beats, product pipeline advancements, and analyst consensus leaning buy. Key risks include execution of recent acquisitions and reliance on key products like Opzelura, but institutional sentiment remains strong with a consensus price target of $107.88.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
